In a mouse model of CCL4-induced liver cirrhosis, infusion of bone marrow-derived MSCs can reduce liver fibrosis area by decreasing TGF-β levels while enhancing BMP7 levels (117). The gene discussed is TGFB1; the disease is Hepatic fibrosis.